Literature DB >> 19571732

The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome.

Yasuji Matsuoka1, Howard F Andrews, Amanda G Becker, Audrey J Gray, Pankaj D Mehta, Mary C Sano, Arthur J Dalton, Paul S Aisen.   

Abstract

To study the relationship between plasma levels of amyloid beta (Abeta) peptides and dementia in aging individuals with Down syndrome, we investigated the relationship among plasma Abeta, apolipoprotein E genotype and cognitive and clinical factors using baseline specimens form participants in an ongoing clinical trial in individuals with Down syndrome 50 years of age and older. Because of substantial skew in the distribution of peptide levels, analyses used log transformations of the data. The ratio of Abeta42 to Abeta40 was associated with the presence of dementia (P=0.003, df=196, F=9.37); this association persisted after adjustment for age, sex level of mental retardation, and apolipoprotein E genotype. Consistent with recent reports regarding the effect of presenilin mutations on peptide generation, our finding supports the theory that the ratio of Abeta42 to Abeta40 rather than absolute levels of the peptides is important to the pathophysiology of Alzheimer's disease in genetically susceptible populations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571732      PMCID: PMC2787755          DOI: 10.1097/WAD.0b013e3181aba61e

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  22 in total

1.  Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment.

Authors:  Marzia Pesaresi; Carlo Lovati; Pierluigi Bertora; Enrico Mailland; Daniela Galimberti; Elio Scarpini; Pierluigi Quadri; Gianluigi Forloni; Claudio Mariani
Journal:  Neurobiol Aging       Date:  2006-04-25       Impact factor: 4.673

2.  Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

Authors:  P D Mehta; T Pirttilä; S P Mehta; E A Sersen; P S Aisen; H M Wisniewski
Journal:  Arch Neurol       Date:  2000-01

3.  Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.

Authors:  Samir Kumar-Singh; Jessie Theuns; Bianca Van Broeck; Daniel Pirici; Krist'l Vennekens; Ellen Corsmit; Marc Cruts; Bart Dermaut; Rong Wang; Christine Van Broeckhoven
Journal:  Hum Mutat       Date:  2006-07       Impact factor: 4.878

4.  Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms.

Authors:  Mostafa Bentahir; Omar Nyabi; Jan Verhamme; Alexandra Tolia; Katrien Horré; Jens Wiltfang; Hermann Esselmann; Bart De Strooper
Journal:  J Neurochem       Date:  2006-01-09       Impact factor: 5.372

5.  Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease.

Authors:  Tomasz Sobów; Marcin Flirski; Iwona Kłoszewska; Paweł P Liberski
Journal:  Acta Neurobiol Exp (Wars)       Date:  2005       Impact factor: 1.579

6.  Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease.

Authors:  T Iwatsubo
Journal:  Neurobiol Aging       Date:  1998 Mar-Apr       Impact factor: 4.673

7.  Plasma levels of amyloid beta 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome.

Authors:  S Cavani; A Tamaoka; A Moretti; L Marinelli; G Angelini; S Di Stefano; G Piombo; V Cazzulo; S Matsuno; S Shoji; Y Furiya; D Zaccheo; F Dagna-Bricarelli; M Tabaton; H Mori
Journal:  Am J Med Genet       Date:  2000-11-27

8.  Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

Authors:  Marieke van Oijen; Albert Hofman; Holly D Soares; Peter J Koudstaal; Monique M B Breteler
Journal:  Lancet Neurol       Date:  2006-08       Impact factor: 44.182

9.  Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease.

Authors:  J J Kulstad; P S Green; D G Cook; G S Watson; M A Reger; L D Baker; S R Plymate; S Asthana; K Rhoads; P D Mehta; S Craft
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

10.  Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome.

Authors:  Nicole Schupf; Bindu Patel; Deborah Pang; Warren B Zigman; Wayne Silverman; Pankaj D Mehta; Richard Mayeux
Journal:  Arch Neurol       Date:  2007-07
View more
  16 in total

Review 1.  Body fluid biomarkers in Alzheimer's disease.

Authors:  Huan Lu; Xi-Chen Zhu; Teng Jiang; Jin-Tai Yu; Lan Tan
Journal:  Ann Transl Med       Date:  2015-04

2.  The AT(N) framework for Alzheimer's disease in adults with Down syndrome.

Authors:  Michael S Rafii; Beau M Ances; Nicole Schupf; Sharon J Krinsky-McHale; Mark Mapstone; Wayne Silverman; Ira Lott; William Klunk; Elizabeth Head; Brad Christian; Florence Lai; H Diana Rosas; Shahid Zaman; Melissa E Petersen; Andre Strydom; Juan Fortea; Benjamin Handen; Sid O'Bryant
Journal:  Alzheimers Dement (Amst)       Date:  2020-10-27

3.  Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.

Authors:  Elizabeth Head; Eric Doran; Mihaela Nistor; MaryAnn Hill; Frederick A Schmitt; Richard J Haier; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome.

Authors:  Nicole Schupf; Annie Lee; Naeun Park; Lam-Ha Dang; Deborah Pang; Alexander Yale; David Kyung-Taek Oh; Sharon J Krinsky-McHale; Edmund C Jenkins; José A Luchsinger; Warren B Zigman; Wayne Silverman; Benjamin Tycko; Sergey Kisselev; Lorraine Clark; Joseph H Lee
Journal:  Neurobiol Aging       Date:  2015-06-19       Impact factor: 4.673

Review 5.  Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease.

Authors:  Robert A Rissman; John Q Trojanowski; Leslie M Shaw; Paul S Aisen
Journal:  J Neural Transm (Vienna)       Date:  2012-02-22       Impact factor: 3.575

6.  Frontal white matter integrity in adults with Down syndrome with and without dementia.

Authors:  David Powell; Allison Caban-Holt; Gregory Jicha; William Robertson; Roberta Davis; Brian T Gold; Frederick A Schmitt; Elizabeth Head
Journal:  Neurobiol Aging       Date:  2014-02-04       Impact factor: 4.673

Review 7.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

8.  Blood-based biomarkers for Down syndrome and Alzheimer's disease: A systematic review.

Authors:  Melissa E Petersen; Sid E O'Bryant
Journal:  Dev Neurobiol       Date:  2019-09-03       Impact factor: 3.964

Review 9.  Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome.

Authors:  Panagiotis Zis; Andre Strydom
Journal:  Free Radic Biol Med       Date:  2017-09-01       Impact factor: 7.376

Review 10.  Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker.

Authors:  Jon B Toledo; Leslie M Shaw; John Q Trojanowski
Journal:  Alzheimers Res Ther       Date:  2013-03-08       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.